Greenwich LifeSciences

GLSINasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$278.739 M

$18.99 +3.26%

Close of 18 Sept 2026

Revenue

—

Not reported

Earnings

-$19.4M

Loss-making

Shares outstanding

14,678,208

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 499 →

#239AmarinAMRN$287.9M
#240Fulcrum TherapeuticsFULC$286.9M
#241Greenwich LifeSciencesGLSI$278.7M
#242Pyxis OncologyPYXS$277.7M
#243Yarrow BioscienceYARW$272.5M

Insiders buying

All insider buying →

3 open-market purchases by officers and directors of Greenwich LifeSciences, worth $97.0K. Grants and option exercises are excluded.

Snehal PatelCEO and CFO$29.6K
2,200 shares at $13.43 on 28 Jul 2026 · filed 30 Jul 2026
Snehal PatelCEO and CFO$20.4K
1,500 shares at $13.62 on 27 Jul 2026 · filed 29 Jul 2026
Snehal PatelCEO and CFO$47.0K
3,600 shares at $13.06 on 23 Jul 2026 · filed 27 Jul 2026

What if Greenwich LifeSciences were worth as much as…

Open the what-if tool →

Gold $30.4T

$2,070,243

Per share 109,018× higher

Bitcoin $1.64T

$111,459.65

Per share 5,869× higher

Nvidia $5.36T

$364,942.85

Per share 19,218× higher

Or at a round number

$500.0M $1.00B $2.00B $5.00B

Where these numbers come from

Share counts and financials for Greenwich LifeSciences are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 19 Sept 2026. Read the methodology.